studies

mHNSCC - L1 - all population, pembrolizumab alone vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.83 [0.70; 0.99] 0.83[0.70; 0.99]KEYNOTE-048 (P vs C ; all population), 201910%601NAnot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 1.34 [1.13; 1.59] 1.34[1.13; 1.59]KEYNOTE-048 (P vs C ; all population), 201910%601NAnot evaluable objective responses (ORR)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.36 [0.25; 0.53] 0.36[0.25; 0.53]KEYNOTE-048 (P vs C ; all population), 201910%601NAnot evaluable AE (any grade)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.31 [0.22; 0.44] 0.31[0.22; 0.44]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable AE leading to death (grade 5)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.84 [0.48; 1.48] 0.84[0.48; 1.48]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.36 [0.23; 0.55] 0.36[0.23; 0.55]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable TRAE (any grade)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.05 [0.02; 0.09] 0.05[0.02; 0.09]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.09 [0.06; 0.13] 0.09[0.06; 0.13]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.35 [0.09; 1.34] 0.35[0.09; 1.34]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 1.92 [0.06; 57.35] 1.92[0.06; 57.35]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.04 [0.01; 0.16] 0.04[0.01; 0.16]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.16 [0.02; 1.31] 0.16[0.02; 1.31]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Blood and lymphatic system disorders TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.02 [0.01; 0.07] 0.02[0.01; 0.07]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Blood creatinine increased TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37] 0.96[0.02; 48.37]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.13; 6.84] 0.96[0.13; 6.84]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37] 0.96[0.02; 48.37]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.12 [0.01; 0.94] 0.12[0.01; 0.94]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.19 [0.02; 1.62] 0.19[0.02; 1.62]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Endocrine disorders TRAE (grade 3-4) detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 5.79 [0.29; 116.06] 5.79[0.29; 116.06]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.25 [0.07; 0.92] 0.25[0.07; 0.92]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.07 [0.02; 0.23] 0.07[0.02; 0.23]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable General disorders and administration site conditions TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.19 [0.08; 0.46] 0.19[0.08; 0.46]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 3.85 [0.17; 85.65] 3.85[0.17; 85.65]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 1.92 [0.06; 57.35] 1.92[0.06; 57.35]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 1.92 [0.06; 57.35] 1.92[0.06; 57.35]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.31 [0.06; 1.57] 0.31[0.06; 1.57]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47] 0.03[0.00; 0.47]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Metabolism and nutrition disorders TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.26 [0.14; 0.49] 0.26[0.14; 0.49]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Mucosal inflammation TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.13 [0.03; 0.58] 0.13[0.03; 0.58]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Myocarditis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37] 0.96[0.02; 48.37]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.48 [0.02; 14.29] 0.48[0.02; 14.29]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47] 0.03[0.00; 0.47]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Nephritis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 3.85 [0.17; 85.65] 3.85[0.17; 85.65]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsOut of scaleKEYNOTE-048 (P vs C ; all population), 2019 0.01 [0.00; 0.11] 0.01[0.00; 0.11]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37] 0.96[0.02; 48.37]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 2.42 [0.46; 12.55] 2.42[0.46; 12.55]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Rash TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.11 [0.02; 0.47] 0.11[0.02; 0.47]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.29 [0.11; 0.73] 0.29[0.11; 0.73]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Stomatitis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.05 [0.00; 0.80] 0.05[0.00; 0.80]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.04 [0.00; 0.27] 0.04[0.00; 0.27]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37] 0.96[0.02; 48.37]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Uveitis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37] 0.96[0.02; 48.37]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.09 [0.01; 1.73] 0.09[0.01; 1.73]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Weight decreased TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.06; 15.37] 0.96[0.06; 15.37]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.19 [0.02; 1.62] 0.19[0.02; 1.62]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Acute kidney injury AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 1.93 [0.35; 10.60] 1.93[0.35; 10.60]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Anaemia AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.24 [0.13; 0.44] 0.24[0.13; 0.44]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Asthenia AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.31 [0.08; 1.16] 0.31[0.08; 1.16]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Blood and lymphatic system disorders AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.10 [0.06; 0.18] 0.10[0.06; 0.18]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.28 [0.08; 1.03] 0.28[0.08; 1.03]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.23 [0.05; 1.11] 0.23[0.05; 1.11]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 2.26 [0.58; 8.83] 2.26[0.58; 8.83]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Fatigue AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.60 [0.26; 1.42] 0.60[0.26; 1.42]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Febrile neutropenia AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47] 0.03[0.00; 0.47]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Gastrointestinal disorders AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.33 [0.20; 0.56] 0.33[0.20; 0.56]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable General disorders and administration site conditions AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.42 [0.23; 0.75] 0.42[0.23; 0.75]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Hypertension AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 7.74 [0.41; 147.13] 7.74[0.41; 147.13]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Hypothyroidism AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37] 0.96[0.02; 48.37]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Increase AST AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.38 [0.07; 1.97] 0.38[0.07; 1.97]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Leucopenia AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47] 0.03[0.00; 0.47]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Metabolism and nutrition disorders AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.51 [0.33; 0.77] 0.51[0.33; 0.77]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Mucosal inflammation AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.25 [0.08; 0.75] 0.25[0.08; 0.75]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Nausea AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.44] 0.03[0.00; 0.44]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Nervous system disorders AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.40 [0.18; 0.85] 0.40[0.18; 0.85]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Neutropenia AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.01 [0.00; 0.09] 0.01[0.00; 0.09]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Pneumonitis AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.80 [0.41; 1.56] 0.80[0.41; 1.56]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Rash AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.11 [0.02; 0.47] 0.11[0.02; 0.47]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Renal and urinary disorders AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 1.15 [0.35; 3.81] 1.15[0.35; 3.81]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Respiratory, thoracic and mediastinal disorders AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 2.17 [1.12; 4.18] 2.17[1.12; 4.18]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Sepsis AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 2.91 [0.58; 14.53] 2.91[0.58; 14.53]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Skin and subcutaneous tissue disorders AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 1.61 [0.58; 4.50] 1.61[0.58; 4.50]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Stomatitis AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.05 [0.00; 0.80] 0.05[0.00; 0.80]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.25] 0.03[0.00; 0.25]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Vascular disorders AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.76 [0.35; 1.64] 0.76[0.35; 1.64]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Vomiting AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.12 [0.01; 0.94] 0.12[0.01; 0.94]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Weight decreased AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 2.26 [0.58; 8.83] 2.26[0.58; 8.83]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-06-01 14:43 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 102 - treatments: 359,575,577,576,869

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons